CSF2RA
Granulocyte-macrophage colony-stimulating factor receptor subunit alpha
As of the edition of 20 October 2026, CSF2RA (granulocyte-macrophage colony-stimulating factor receptor subunit alpha, UniProt P15509) has 2 drugs tested at it and 4 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P15509
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 2
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Urinary and reproductive; Infections; Digestive system; Pregnancy and women's health
- Registered trials of its drugs
- 332
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sargramostim | Marketed | Phase 3 | Ended 2025 |
| Mavrilimumab | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Undetermined | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Nobelpharma | Route B |
| Partner Therapeutics | Route B |
The other 1 company at CSF2RA
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at CSF2RA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.